RxDoctor Payments Data

Fayaz Shawl, MD

Cardiology · Takoma Park, MDNPI 1265482368

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,218 of the $1,956 with a category attached, or 62.3%. Abbott accounts for 68.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $1,472 and has fallen 96.5% since, to $51 in 2025.

$1,956in general payments, 2019–2025

Across 34 payments — averaging $57.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Edwards Lifesciences$341
  • Medtronic$139
  • Boston Scientific$59
  • Abiomed$26
  • Philips North America LLC$18
  • plus $29 from 2 others
$169,241in research payments, 2019–2025

Across 152 payments — averaging $1113.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Inc.$139K
  • Contego Medical, Inc$29K
  • Cordis Corporation$2K

What the payments were for

  • Travel & lodging$1,21862%
  • Food & beverage$73838%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,956 in reported general payments places this provider in the 75th percentile of 44 cardiology providers in Maryland.

See all cardiology providers in Maryland

Medicare billing

Part B allowed, 2024
$250,308
Medicare patients
481
Services billed
1,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$49,994
Ranolazine ErRanolazine73$8,861
Metoprolol Succinate121$2,305
ClopidogrelClopidogrel Bisulfate152$2,274
Atorvastatin Calcium105$1,763
Rosuvastatin Calcium68$1,717
Olmesartan Medoxomil13$890
Ezetimibe22$843
Losartan Potassium76$806
Isosorbide Mononitrate ErIsosorbide Mononitrate35$654
Amlodipine Besylate72$603
Nitroglycerin24$457
Nitroglycerin PatchNitroglycerin11$338
Pantoprazole Sodium15$261
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide13$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$49,99445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 44 cardiology providers in Maryland.

Other cardiology in Takoma Park

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →